The annual meetings of the American Society of Clinical Oncology (ASCO) and the Euro­pean He­ma­tol­ogy Asso­ci­a­tion (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physi­cians from around the world, and featured a myriad of oral pre­sen­ta­tions, posters, and e-abstracts summarizing the re­­sults of new on­col­ogy- and he­ma­tol­ogy-related re­search.

Included in the re­search pre­sented at the two meetings were more than 200 stud­ies discussing new mul­ti­ple myeloma-related findings.

In addi­tion to the two large meetings held earlier this month, the Inter­na­tion­al Myeloma Work­ing Group (IMWG) …

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a num­ber of poster pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, re­search re­­sults are made avail­able for review by meeting attendees in the form of posters, each of which summarizes the re­­sults of a single study. Each poster is typ­i­cally about two feet high by three or four feet in length, and all posters during a ses­sion are dis­played throughout a large conference hall.

Most of the myeloma-related …

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier to­day, May 29, and will go through June 2 in Chicago.

Approximately 30,000 physicians and re­searchers from all over the world are ex­pec­ted to attend the five-day meeting to discuss cur­rent re­search in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all types of cancer, in­clud­ing many pre­sen­ta­tions focused spe­cif­i­cally on mul­ti­ple myeloma. In fact, more than 90 myeloma-related stud­ies are scheduled to be pre­sented, in one form or another, in con­nec­tion with the …

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a hap­pen­ing time for the mul­ti­ple myeloma com­munity. The short span of time witnessed the pub­li­ca­tion of up­dated criteria for the diag­nosis of mul­ti­ple myeloma from the Inter­na­tional Myeloma Work­ing Group (IMWG). In addi­tion, the 56^th annual meeting of the American Society of He­ma­tol­ogy (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster pre­sen­ta­tions.

Therefore, it is again …

Saturday was the official first day of the 2014 American Society of Hema­tology (ASH) annual meeting. The day featured a wide range of in­ter­est­ing pre­sen­ta­tions about mul­ti­ple myeloma.

Oral pre­sen­ta­tions about new treat­ments under devel­op­ment were given mid-day and were summarized in a Beacon ASH Daily Update published yes­ter­day morn­ing.

During Saturday evening, a poster session took place where im­por­tant new re­search findings were summarized in posters dis­played throughout two separate large conference halls.

The stud­ies covered a variety of myeloma-related topics, ranging from new treat­ments being devel­oped for myeloma, com­bi­na­tion ther­a­pies …

The 2014 annual meeting of the American Society of He­ma­tol­ogy (ASH) starts tomorrow, De­cem­ber 5, in San Francisco, and will con­tinue until next Tuesday.

The ASH annual meeting is one of sev­er­al large med­i­cal conferences where myeloma-related re­search findings are pre­sented each year.  However, from a mul­ti­ple myeloma perspective, the ASH meeting is generally the most im­por­tant of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The pre­sen­ta­tions will summarize cur­rent re­search on a wide range of topics, in­clud­ing the biology of the dis­ease …

• This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma
• This new Phase I initiated by Bristol-Myers Squibb is the first combination trial of lirilumab in a hematological tumor type

Marseille, France (Press Release) - Innate Pharma SA (the "company" -  euronext paris:FR0010331421 - IPH), the innate immunity com­pany devel­op­ing first-in-class thera­peutic anti­bodies for cancer and in­flam­ma­tory dis­eases, to­day an­nounced that a new Phase I com­bi­na­tion trial with lirilumab, a …